Ahead of the Q1 report, we look for a continuation of the recently strong sales growth trends (Q1 sales up 20% y/y). SyntheticMR, in our view, has begun 2021 with newfound confidence and we see several levers of growth throughout the year. We lift our 2020-23 adj. EBIT estimates by 6-10% and derive a new DCF-based fair value range of SEK 424-559 (previously SEK 391-516) per share.

Link to the analysis